



6

1

SEQUENCE LISTING

<110> CLARK, JONATHAN
LAMONT, ALAN
WILLIAMS, DAVID

<120> A METHOD FOR MAPPING THE ACTIVE SITES BOUND BY ENZYMES
THAT COVALENTLY MODIFY SUBSTRATE MOLECULES

<130> 179-54

<140> 10/020,436
<141> 2001-12-18

<150> 09/530,431
<151> 2000-07-26

<150> PCT/GB98/03259
<151> 1998-10-30

<150> GB 9722818.3
<151> 1997-10-30

<160> 19

<170> PatentIn Ver. 2.1

<210> 1
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Consensus
peptide

<222>
<223> Biotin-epsilon-aminohexanoic acid is linked to the
aspartic acid residue at position 1

<220>
<221> MOD_RES
<222> (8)
<223> Norleucine

<400> 1
Asp Glu Glu Asp Tyr Phe Glu Xaa
1 5

<210> 2
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

```
<400> 2
ccgggatccg ccatgcccat ggacacgagc gtgtat 36

<210> 3
<211> 57
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 3
gggggatcct cagtggtggt ggtggtggtg ggcacaggca gcctcagcct tctgtgt 57

<210> 4
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 4
Asp Glu Glu Asp Tyr
 1           5

<210> 5
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 5
Asp Glu Glu Tyr Phe
 1           5

<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 6
Asp Glu Tyr Glu Phe
 1           5

<210> 7
<211> 5
<212> PRT
```

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (5)

<223> Norleucine

<400> 7

Asp Tyr Phe Glu Xaa
1 5

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 8

Asp Glu Glu Asp Tyr
1 5

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 9

Asp Glu Glu Tyr Asp
1 5

<210> 10

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 10

Asp Glu Tyr Glu Asp
1 5

<210> 11

<211> 5

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 11
Asp Tyr Glu Glu Val
1 5

<210> 12
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (5)
<223> Norleucine

<400> 12
Tyr Ser Ile Ile Xaa
1 5

<210> 13
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 13
Asp Glu Glu Glu Tyr
1 5

<210> 14
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 14
Asp Glu Glu Tyr Phe
1 5

<210> 15
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 15
Asp Glu Tyr His Asn
1 5

<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 16
Asp Tyr His Leu Phe
1 5

<210> 17
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 17
Tyr Pro Ile Glu Val
1 5

<210> 18
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 18
Ser Tyr Phe His Glu
1 5

<210> 19
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 19
Lys Lys Lys Lys Ala Asp Glu Glu Asp Tyr Phe Ile Pro Pro Ala
1 5 10 15